¿Existe un espacio para los análogos de la incretina como terapia para el sobrepeso, la obesidad y la prevención de la enfermedad cardio-metabólica?

Translated title of the contribution: Is there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention?

José López-López, Karina A. Di Stefano, Elizabeth Velásquez, Paul Anthony Camacho, Patricio López-Jaramillo

Research output: Contribution to journalShort surveypeer-review

2 Scopus citations

Abstract

Introduction: During the last decades there has been a gradual increase of cardiovascular diseases, who have become the main cause of death in the world and especially in Latin American countries, despite having identified preventable cardiovascular risk factors that explain around 90% of myocardial infarctions and cerebrovascular accidents. Therefore, it is require to implement actions that will allow to control cardiovascular risk factors, including being overweight or obese. Motivation: To review the effect of GLP-1 receptor agonists, including liraglutide, in controlling cardiovascular risk factors, particularly excess weight and obesity and the subsequent prevention of cardiovascular diseases. Methods: Evidence were searched by means of boolean operators and cross references in databases MEDLINE, LILACS and Google Scholar. Conclusions: GLP-1 receptor agonists can be a pharmacological alternative to control excess weight and obesity, and may help in preventing cardiovascular disease, though some questions remain regarding the benefits of its use in our field.

Translated title of the contributionIs there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention?
Original languageSpanish
Pages (from-to)200-209
Number of pages10
JournalRevista Colombiana de Cardiologia
Volume23
Issue number3
DOIs
StatePublished - 1 May 2016

Fingerprint

Dive into the research topics of 'Is there a space for incretin mimetics as a therapy for excess weight, obesity and cardiometabolic disease prevention?'. Together they form a unique fingerprint.

Cite this